Literature DB >> 5578236

Modification of the cardiovascular effects of L-dopa by decarboxylase inhibitors.

A M Watanabe, L C Parks, I J Kopin.   

Abstract

Intravenously infused L-dopa (0.3 mg/kg per min) produced hypertension and cardiac arrhythmias in halothane anesthetized dogs. Biochemical studies showed that the heart, kidney, and brain of these animals accumulated significant amounts of catecholamines formed from the administered precursor. Pretreatment of dogs with an extracerebral inhibitor of dopa decarboxylase [D,L-alpha-hydrazino-alpha-methyl-beta-(3.4-dihydroxyphenyl) propionic acid] prevented the development of hypertension and arrhythmias with infusion of L-dopa. Instead, these animals developed significant hypotension. The heart and kidney of these animals accumulated markedly reduced amounts of catecholamines formed from L-dopa compared with dogs receiving L-dopa alone: the amount of catecholamines accumulated in brain was unchanged. L-dopa, after extracerebral decarboxylase inhibition, appeared to produce hypotension by reducing peripheral vascular resistance without altering sympathetic nerve function. During hypotension, cardiac output was not altered and arterial pressure in perfused hindlimbs fell, even though flow was maintained. The pressor response to intravenous injections of norepinephrine and dopamine was unchanged. Hindlimb arterial pressure response to direct electrical stimulation of the lumbar sympathetic trunk was also unchanged. Pretreatment with a drug which inhibits brain as well as extracerebral dopa decarboxylase [D,L-seryl-2,3,4-trihydroxybenzylhydrazine hydrochloride] abolished all effects of L-dopa on blood pressure. In these animals, there was a marked reduction of catecholamine formation from L-dopa in the brain as well as the heart and kidney. It appears that L-dopa produces opposite effects on blood pressure depending on the site of accumulation of its metabolic products, dopamine and norepinephrine. If L-dopa is rapidly decarboxylated to catecholamines in peripheral organs, hypertension and cardiac arrhythmias occur. If peripheral dopa decarboxylase is selectively inhibited, a centrally mediated hypotensive effect, probably secondary to the accumulation of catecholamines in the brain, becomes apparent. If dopa decarboxylase is inhibited in the brain in addition to extracerebral organs, L-dopa has no effect on blood pressure.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 5578236      PMCID: PMC292063          DOI: 10.1172/JCI106611

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  15 in total

1.  Effect of various decarboxylase inhibitors on the cerebral metabolism of dihydroxyphenylalanine.

Authors:  G Bartholini; A Pletscher
Journal:  J Pharm Pharmacol       Date:  1969-05       Impact factor: 3.765

2.  Modification of Parkinsonism--chronic treatment with L-dopa.

Authors:  G C Cotzias; P S Papavasiliou; R Gellene
Journal:  N Engl J Med       Date:  1969-02-13       Impact factor: 91.245

3.  Accumulation of dopamine in the parenchyma after decarboxylase inhibition in the capillaries of brain.

Authors:  J Constantinidis; G Bartholini; R Tissot; A Pletscher
Journal:  Experientia       Date:  1968-02-15

4.  Potentiation and inhbition of some central actions of L(-)-dopa by decarboxylase inhibitors.

Authors:  V J Lotti; C C Porter
Journal:  J Pharmacol Exp Ther       Date:  1970-04       Impact factor: 4.030

5.  Effect of L-dopa alone and in combination with an extracerebral decarboxylase inhibitor on blood pressure and some cardiovascular reflexes.

Authors:  A M Watanabe; T N Chase; P V Cardon
Journal:  Clin Pharmacol Ther       Date:  1970 Sep-Oct       Impact factor: 6.875

6.  Treatment of parkinsonism with levodopa.

Authors:  M D Yahr; R C Duvoisin; M J Schear; R E Barrett; M M Hoehn
Journal:  Arch Neurol       Date:  1969-10

7.  Surgical infiltration of pressor drugs and their interaction with volatile anaesthetics.

Authors:  R L Katz; G J Katz
Journal:  Br J Anaesth       Date:  1966-09       Impact factor: 9.166

8.  Subcellular distribution and release by sympathetic nerve stimulation of dopamine and alpha-methyl dopamine.

Authors:  J M Musacchio; J E Fischer; I J Kopin
Journal:  J Pharmacol Exp Ther       Date:  1966-04       Impact factor: 4.030

9.  Treatment of Parkinson's syndrome with L dihydroxyphenylalanine (levodopa).

Authors:  F McDowell; J E Lee; T Swift; R D Sweet; J S Ogsbury; J T Kessler
Journal:  Ann Intern Med       Date:  1970-01       Impact factor: 25.391

10.  Hypotension caused by L-dopa.

Authors:  D B Calne; J Brennan; A S Spiers; G M Stern
Journal:  Br Med J       Date:  1970-02-21
View more
  4 in total

1.  Phosphaturic effect of dopamine in dogs. Possible role of intrarenally produced dopamine in phosphate regulation.

Authors:  J L Cuche; G R Marchand; R F Greger; R C Lang; F G Knox
Journal:  J Clin Invest       Date:  1976-07       Impact factor: 14.808

2.  Dopaminergic inhibition of vasopressin-stimulated water flow in the toad bladder: evidence for local formation of dopamine.

Authors:  J A Arruda; S Sabatini
Journal:  J Membr Biol       Date:  1982       Impact factor: 1.843

3.  The cardiovascular effects of L-dopa in the pithed rat.

Authors:  E Eden; P A Nasmyth
Journal:  Br J Pharmacol       Date:  1974-08       Impact factor: 8.739

4.  Levodopa combined with peripheral decarboxylase inhibition in Parkinson's disease.

Authors:  A Barbeau; H Mars; M I Botez; M Joubert
Journal:  Can Med Assoc J       Date:  1972-06-10       Impact factor: 8.262

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.